Lyra Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference
30 juil. 2020 16h05 HE
|
Lyra Therapeutics
WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update
24 juil. 2020 08h30 HE
|
Lyra Therapeutics
WATERTOWN, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics Announces Robert Richard, Ph.D., as Senior Vice President of Research and Development
07 juil. 2020 08h30 HE
|
Lyra Therapeutics
WATERTOWN, Mass., July 07, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases
02 juil. 2020 11h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, July 02, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin diseases and healthy ageing,...
Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress
29 juin 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 2 systemic sclerosis (SSc) analyses show ACR CRISS score correlates with improvements from baseline in how patients feel and function through two years in the lenabasum Phase 2 open-label...
Lyra Therapeutics Set to Join the Russell 2000® Index and Russell 3000® Index
25 juin 2020 08h00 HE
|
Lyra Therapeutics
WATERTOWN, Mass., June 25, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
28 mai 2020 16h05 HE
|
Lyra Therapeutics
WATERTOWN, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Chronic Obstructive Pulmonary Disease Market Size Worth Around USD 24.3 Billion by 2026: Acumen Research and Consulting
19 févr. 2019 07h00 HE
|
Acumen Research and Consulting
According to a new research report titled ‘Chronic Obstructive Pulmonary Disease Treatment Market (By Drug Class: Bronchodilators, Combination, Phosphodiesterase Type 4 Inhibitors, Mucokinetics,...
BioDelivery Sciences Announces Further Significant Expanded Preferred Coverage For BELBUCA®
01 nov. 2018 16h10 HE
|
BioDelivery Sciences International, Inc.
More than 100 million Covered Lives Now Have Preferred Access to BELBUCA RALEIGH, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly...
BioDelivery Sciences to Report Second-Quarter 2018 Financial Results on August 9, 2018
24 juil. 2018 16h30 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., July 24, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it will report its second quarter 2018 financial results after the close...